Our certified DBI-EPIbreath® test provides real-time, non-invasive drug monitoring and risk prediction for people with epilepsy.
DBI-EPIbreath®
50 million people worldwide live with epilepsy, a sixth of them are children. Medical treatment helps in ~70% of cases and often requires therapeutic drug monitoring.
Therapeutic drug monitoring requires blood sampling and frequent visits to healthcare providers. Drug concentrations in blood often do not correlate with improved clinical outcome and minimal side effects.
Metabolization of medication is highly specific to individuals. This is especially critical for medications with a narrow therapeutic range. Valproic acid (VPA) is such a medication and is the treatment of choice for generalized or difficult to classify epilepsy.
Our certified DBI-EPIbreath® test only needs an exhale to estimate the drug concentration of VPA in blood and the risks of severe side effects and seizures. Thus, it is ideally suited to support healthcare providers in their treatment decisions in epilepsy.
News
Whitepaper
Do you want to learn more about how DBI-EPIbreath® acts as a complementary diagnostics tool for patient monitoring and stratification?
We recently published a whitepaper on the topic:
Non-invasive, real-time therapeutic drug monitoring of valproic acid in the breath of epilepsy patients
You can get it for free by following the button below.
How it works
Do a simple breath test
Data is analyzed by DBI’s machine learning (ML) algorithms in cloud
See results in 10 minutes
Drug monitoring and decision support
- In real-time
- Non-invasive
- Supports precision medicine